Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medtronic | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hypothesis:
ITB bolus can have antinociceptive effect on neuropathic pain in spinal cord injury patients, which could depend on the subtype of pain, or on the lesion level, cervical or thoracic spinal cord injury.
Objective:
To study the effect of intrathecal baclofen bolus on neuropathic pain in patients with spinal cord injury at cervico-dorsal level.
Primary Endpoint:
Effect of intrathecal baclofen bolus in neuropathic pain (measured using the Neuropathic Pain Inventory Scale, the Brief Pain Inventory and the Numerical Rating Scale) in spinal cord injury at cervico-dorsal level.
Secondary Endpoints:
The study will be a randomized, double-blind (patients and who will realize the clinical and neurophysiologic evaluation), placebo-controlled trial. We will recruit 10-12 patients with SCI with complete or incomplete lesion at cervical or thoracic level to be randomly distributed in two study groups: ITB bolus group and a placebo group.
In 6-8 months, we will administer an intrathecal baclofen bolus of 50 µg (1ml) in 5-6 SCI patients or 1ml of physiologic serum subcutaneously in the other 5-6 SCI patients.
Before the intrathecal baclofen or placebo bolus is administered, patients will be evaluated for neuropathic pain, using the Neuropathic Pain Inventory Scale, Brief Pain Inventory and Numerical Rating Scale. Spasticity and spasms will also be measured by the Modified Ashworth Scale, the Visual Analogue Scale and the Penn Spasm. After that, patients will also undergo, early in the morning when the intrathecal baclofen or placebo bolus will be administered, a neurophysiology assessment (warm perception threshold, heat pain perception threshold, evoked pain perception and contact heat evoked potentials).
After the neurophysiological evaluation, patients will receive an intrathecal baclofen bolus of 50 µg or placebo (randomization). After the intrathecal baclofen or placebo injection, a clinical and neurophysiological examination, of neuropathic pain and spasticity and spasms, will be repeated at 1, 2 and 4 hours after the bolus administration. Moreover, Kumru et al. (2013) reported that the 50 µg intrathecal baclofen bolus reduced the pain perception threshold and evoked acute pain perception in patients with SCI.
During all evaluation period, the patients continue with their analgesic, antispastic and/or any other stable medication.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| intrathecal baclofen bolus | Active Comparator | In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg. |
|
| placebo | Placebo Comparator | In the placebo group: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intrathecal baclofen bolus | Drug | An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Neuropathic Pain Inventory Scale (NPIS) | a self-questionnaire specifically designed to evaluate the different symptoms of neuropathic pain and includes 10 descriptors that allow discrimination and quantification of five distinct clinically relevant dimensions of neuropathic pain syndromes and that are sensitive to treatment | Change from baseline in neuropathic pain at 4hours |
| Measure | Description | Time Frame |
|---|---|---|
| Modified Ashworth Scale (MAS) | is to measure spasticity in patients who have lesions of the central nervous system or neurological disorders. | Change from baseline in spasticity at 1, 2 and 4hours |
| Modified Penn Spasm Frequency Scale |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hatice Kumru, MD PhD | Neurologist | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Guttmann | Badalona | Barcelona | 08916 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009437 | Neuralgia |
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating |
|
|
2 component self-report measure of the frequency of reported muscle spasms which is commonly used to quantify spasticity.
| Change from baseline in spasticity at 4hours |
| Visual Analogue Scale (VAS) for spasticity | Consists 10cm line for patient self-reporting of spasticity last 24hours | Change from baseline in spasticity at 4 hours |
| warm and heat pain perception threshold | it is quantitative sensory perception test for warm perception threshold and heat pain perception threshold | Change from baseline in warm and pain perception at 4hours |
| evoked pain perception | it is quantitative sensory perception test for acute induced pain perception measurement | Change from baseline in evoked acute pain perception at 4hours |
| contact heat evoked potentials. | It is an evoked potential induced with heat painful stimulus | Change from baseline in evoked potential with heat pain at 4hours |
| Brief Pain Inventory (BPI) | The BPI allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. | Change from baseline in pain at 4hours |
| Numerical Rating Scale (NRS) for neuropathic pain | Varies between 0-10 point (no pain- more severe pain) for patient self-reporting of pain for actual pain | Change from baseline in pain at 4hours |
| D009461 |
| Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |